For myocardial infarction, cardiac troponins (I and T) are widely considered adequate diagnostic biomarkers based on their myocardial tissue specificity and their association with important clinical outcomes. 4 In contrast, assessment of renal status by sCr is not straightforward, because defective excretion of sCr can result from extrarenal hypovolemia, impaired blood perfusion, intrinsic kidney causes (attributable to sepsis, ischemia, drugs, toxins, interstitial or glomerular causes, or a combination of these conditions), or postrenal disease. 5 It is implausible, therefore, that creatinine, an end-product of muscle catabolism freely filtered by the glomerulus and secreted by the tubule, can discriminate between causes of renal dysfunction. Although measurement of sCr is cheap, widely available, and standardized, its disadvantages include not only the many inducers of elevated sCr, but also the large number of conditions affecting its non-GFR determinants, including renal reserve, muscle metabolism, protein intake, volume of distribution, medications, and extrarenal degradation. In fact, equations estimating GFR using sCr have variable bias across populations, and are imprecise despite standardization of sCr assays and inclusion of age, sex, race, and body size as surrogates for creatinine generation. 5 These equations assume that sCr is a steady-state marker of creatinine production and disposal, conditions that do not apply to AKI. An alternative to creatinine, cystatin C, is a protein produced in all nucleated cells and distributed in extracellular fluid. It is freely filtered and mostly reabsorbed and catabolized by the proximal tubule. Cystatin C is not affected by muscle mass or diet and is less strongly associated with age, sex, and race than creatinine, but smoking, inflammation, adiposity, thyroid diseases, malignancy, and glucocorticoids influence cystatin C levels, diminishing their value as a measure of renal excretory performance. 5 In addition, international standardization of the cystatin C assay is not finalized. 5 Estimation of GFR using creatinine, cystatin C, or both has not been validated in acutely ill patients, in whom these estimates appear to be inaccurate in comparison with 4-hour urinary creatinine clearance for detection of renal function changes. 6 It is disappointing, therefore, that the severity of AKI is predominantly classified according to sCr changes or cystatin changes. 5, 7 This is because, in the absence of steady state, a patient may have florid tubular damage at presentation without significant changes in sCr attributable to renal reserve and consequent delay in achievement of detectable changes in this analyte. Conversely, the correlation of an increase in sCr levels with better outcomes during the treatment of HF suggests that elevation of this analyte identifies physiological, volume-sensitive responses to diuretics, rather than tubular damage. 2 Ahmad and colleagues expand the evidence that, in the context of aggressive diuresis of fluid-overloaded patients with HF, WRF, as defined by creatinine-based estimation of GFR, occurs without obvious renal tubular injury. 3 These findings support the notion that sCrbased AKI stages inaccurately describe the severity of excretory dysfunction and fail to provide information on whether tubular damage, if it occurs at all, is reabsorptive or excretory. 7, 8 Advances in kidney transcriptomics and urinary proteomics suggest that kidney genes and their encoded proteins can be specific for certain stimuli and cellular targets. Serum creatinine is not in this category because it can be elevated to similar extents in different experimental and clinical situations. Xu and colleagues 9 have found that different genetic signatures are activated by renal ischemia versus volume depletion. Differential gene expression was also shown in thousands of patients presenting with a broad range of illnesses. 10 Hence, the dissociation between kidney cell lines transcriptomics/urinary proteomics and sCr identified by Ahmad and colleagues is likely attributable to differences in the intrinsic characteristics of sCr (delayed, insensitive, not specific to tubular damage) and the genetic responses of the kidney (rapid, sensitive, cell-specific, stimulus-specific). 8, 9, 11 Then why are biomarkers of tubular injury, such as those measured by Ahmad and colleagues, not widely used in patients with decompensated HF to distinguish true tubular injury from changes in renal clearance function because of diuresis-driven hemoconcentration? Waikar and colleagues 11 observed that in predictive modeling, the performance of biomarkers as measures of tubular injury is undermined by both use of sCr as the gold standard comparator and a lack of consideration of disease prevalence in the target population. Assuming that, at a certain cutoff value, sCr is 90% sensitive and 90% specific and disease prevalence is 20%, a new biomarker with 100% sensitivity and 100% specificity may seem to have only 69% sensitivity and 97% specificity in comparison with the imperfect gold standard. 11 Therefore, changes in therapy of patients with acute HF based only on sCr increases rather than on biomarker and clinical data are problematic because of the kinetics and non-GFR determinants of creatinine, and because they may trigger adjustments in or discontinuation of symptom-improving and lifesaving antineurohormomal drugs and prevent effective decongestion. 1, 8, 9, 11, 12 Unfortunately, this fact is still viewed with skepticism despite the emerging evidence that unresolved congestion is strongly associated with poor outcomes. 2, 12 In comparison with healthy subjects, even asymptomatic patients with HF have decreased sodium excretion in response to volume expansion. 1 Abnormal fluid handling is associated with physiological abnormalities in multiple organ systems. Increased myocardial water can lead to ischemia and decreased contractility in animals and humans.
1 Deranged hemodynamics, neurohormonal activation, excessive tubular sodium reabsorption, inflammation, oxidative stress, and nephrotoxic medications are important drivers of harmful cardiorenal interactions in patients with HF. 1 Elevation of central venous pressure is rapidly transmitted to the renal veins, causing increased interstitial and tubular hydrostatic pressure, which decreases net glomerular filtration. 1 Increased central venous pressure is independently associated with renal dysfunction and unfavorable outcomes in both acute and chronic HF. 1 Venous congestion itself can produce endothelial activation, upregulation of inflammatory cytokines, hepatic dysfunction, and intestinal villi ischemia. Bacterial endotoxins can then enter the circulation, magnifying the inflammatory milieu created by venous congestion and neurohormonal activity. 1 Thus, the foremost goal in managing patients with decompensated HF is to effectively resolve fluid overload. 1, 12 If a decrease in intravascular volume by fluid removal causes small transient increases in sCr, effective decongestion may still be essential to protect the kidney in the long term. 1, 12 Although there were no consistent changes in neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-dglucosaminidase, and kidney injury molecule-1, suggesting that gross tubular injury cannot account for WRF (in particular, because these 3 biomarkers map to different parts of the nephron and display different mechanisms of activation), Ahmad et al found that a small subset of patients demonstrated increases in biomarker urinary concentrations in the range of tubular damage seen in previous studies (eg, the patients with delta NGAL>115 ng/mg urinary concentration). 3, 10 Yet even in these patients, an increase in biomarkers of tubular injury did not worsen outcomes, suggesting that fluid overload was a greater evil than some degree of renal tubular injury. 1, 3, 12 In addition, NGAL, N-acetyl-β-d-glucosaminidase, and kidney injury molecule-1 levels in the cohort analyzed by Ahmad et al may have been magnified because they were indexed to urine creatinine (the denominator), which decreases with excretory abnormalities. 13 Hence, it seems premature to equate changes in NGAL, N-acetyl-β-d-glucosaminidase, and kidney injury molecule-1 to injury even in the subset of patients with higher biomarker levels until thorough molecular and histological characterization is available for all renal cell types. Finally, is there a possibility that NGAL and kidney injury molecule-1 may be protective during AKI by, respectively, delivering iron and mediating phagocytosis? 14, 15 Unquestionably, Ahmad and colleagues accomplish 2 important goals: they confirm that congestion is associated with poor outcomes in acute HF and shed light on the knowledge gaps in the identification of AKI and the assessment of its severity, because hemodynamically driven changes in sCr were not generally accompanied by changes in biomarkers of tubular damage. Although the absence of consistent changes in biomarkers supports continuation of decongestive treatments, increased confidence in these therapies will require documentation of WRF reversibility.
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